Alistar, A., Morris, B. B., Desnoyer, R., Klepin, H. D., Hosseinzadeh, K., Clark, C., Cameron, A., Leyendecker, J., D'Agostino, R., Topaloglu, U., Boteju, L. W., Boteju, A. R., Shorr, R., Zachar, Z., Bingham, P. M., Ahmed, T., Crane, S., Shah, R., Migliano, J. J., Pardee, T. S., Miller, L., Hawkins, G., Jin, G., Zhang, W., & Pasche, B. (n.d.). safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet oncology, 18(6), 770–778. http://access.bl.uk/ark:/81055/vdc_100046742673.0x000061